Participated · Equity · Jan 2024

Ansel provides a modern supplemental health insurance product that issues cash payouts upon diagnosis for more than 13,000 conditions, with no accident or hospitalization requirements. The company emphasizes a simplified, paperless enrollment and claims experience and has implemented claims automation that leverages medical claims data so members can receive benefits without filing claims. Ansel partners with established insurance carriers and benefits brokerages to distribute its plans and reported a net promoter score of 90 in 2023. The product is available in partnership with carriers across 39 states and the company is working toward nationwide availability. Founded in 2019, Ansel rebranded and adopted its current name and visual identity entering 2024. The company has raised over $50M to date and is using the new capital to expand availability of its supplemental insurance solution nationwide. Brella Insurance offers a tech-enabled supplemental health insurance plan that pays cash on diagnosis for more than 13,000 conditions. The product is designed for distribution through employers, brokers, and strategic partners and emphasizes simple implementation and administration. Brella positions its plan as broader than traditional supplemental products, which the company says are too narrow and have outdated claims and administration processes. The company is actively engaging brokers and employers in Texas and planned launches in additional states in Q2 2021 to support nationwide expansion. Brella says the financing will fund its national expansion and alliances with leading benefits brokerage firms and strategic partners. Since inception the company has raised over $22M in total funding. Brella Insurance provides a supplemental health insurance plan designed for Texas-based employers and their teams. The plan pays cash upon diagnosis of any of more than 13,000 covered conditions, including many complications associated with COVID-19, to complement traditional health insurance. Founded in 2019 by Veer Gidwaney (formerly CEO and co‑founder of Maxwell Health) and previously known as Clara Insurance, the company is focused on employer benefits. Brella has partnered with RGAx and Greenhouse Life Insurance Company, subsidiaries of Reinsurance Group of America, to bring its solution to the employee benefits market. Financially, the company has raised over $7M in total funding after an additional $1.5M round. Brella is actively engaging brokers and employers in Texas to grow adoption.

Participated · Seed · May 2020

Clara Insurance offers a modern supplemental benefit plan designed to provide wide-ranging, personalized coverage with quick cash payments for up to 93% of issues that require immediate medical attention. Plans are customizable, including optional additional coverage for chronic conditions and mental health, and the product has no pre-existing condition exclusions. Members can use payouts for medical bills or everyday expenses such as childcare, groceries, or transportation. Clara's claims technology and member app let users upload photos and file claims in minutes, with payouts delivered in hours rather than weeks, and members have access to a dedicated concierge team. The leadership team includes founder and CEO Veer Gidwaney (formerly of Maxwell Health) and senior hires from AXA US and Guardian Life; advisors and board members include executives from Atlassian, Humana, Two Sigma Ventures, and UnitedHealth. Clara will launch in Texas in summer 2020 and is headquartered in New York City.

Participated · Series B · Jan 2020

ConcertAI is a Cambridge, MA-based provider of enterprise AI and real-world data (RWD) solutions for life sciences and healthcare. The company offers software-as-a-service (SaaS) and data solutions to life sciences and biopharma companies, healthcare providers, contract research organizations (CROs), medical societies, and regulators in the US, Europe, and Japan. Through a “system of evidence” approach, ConcertAI advances data and technologies that underpin new models of clinical development, driven by the pandemic’s acceleration to fully digital and AI-enabled solutions. Its assets include a large, independent oncology research database and patient data composed of clinical, molecular, medical claims, and imaging data. Led by CEO Jeff Elton, PhD., and Executive Chairman Dr. Romesh Wadhwani, the company has expanded its customer base and partnerships to more than 45 life sciences companies and CROs over the past 36 months. Oncology biopharma companies including Janssen and BMS are cited as multi-product strategic partners. The company intends to use the new funding to expand operations and broaden its business reach. Concerto HealthAI provides Real-World Data (RWD) and AI-enabled enterprise technology for precision oncology, assembling a clinical network through partnerships with community oncology networks and an exclusive license with CancerLinQ LLC, a nonprofit subsidiary of the American Society of Clinical Oncology. Its data integrations span all major electronic medical record environments and include next-generation sequencing diagnostic information and patient-reported outcomes. The company’s engineers produce case-aligned, AI-enriched, validated, production-ready RWD products and complementary AI-enabled cloud technologies for precision research and patient solutions. Concerto recently launched a new version of eurekaHealth that combines integrated RWD with advanced machine learning. The company intends to use recent funding to support continued innovation in RWD and technology products and services for regulatory and non-regulatory applications, expansion into adjacent therapy areas, and commercial patient solutions. Concerto HealthAI is based in Boston, MA.